NETANYA, Israel, March 24, 2020 /PRNewswire/ -- CLEW today announced that its TeleICU solution – CLEW-ICU – is being deployed by Tel Aviv Sourasky Medical Center (Ichilov Hospital) and Sheba Medical Center as an innovative new way to manage and treat patients infected with the COVID-19 virus while protecting frontline care workers.
In anticipation of a surge in ICU admissions, both organizations are establishing field-ICU facilities, each of which will be the largest ICU units in Israel. The field-ICU units will use telemedicine technologies to provide remote patient monitoring from centralized command and control facilities.
Based upon a telemedicine architecture, CLEW-ICU uses AI-based predictive analytics to exponentially expand ICU capacity and resources.
- The AI-based algorithms are specifically trained to identify respiratory deterioration in advance, enabling early interventions that might change the clinical outcome, especially in COVID-19 patients.
- The machine learning models enable ICU workers to proactively manage disease severity and workload.
- The system's minute by minute risk stratification provides real-time acuity classification, allowing timely interventions and improved prognosis for critically ill patients.
- As a telemedicine-based solution, the system is used remotely, easily scaling to cope with patient volume surges while reducing a caregiver's exposure risk to infected patients
In the U.S. the CLEW-ICU system is currently undergoing extensive testing in TeleICU facilities at UMass Memorial Medical Center in Worcester, Massachusetts, and WakeMed in Raleigh, North Carolina. The company has submitted its 501K application for potential FDA approval.
Prof. James Blum, MD, FCCM, and Chairman of CLEW's Scientific Advisory Board said, "AI combined with telemedicine is a force multiplier and can be used to provide patient acuity classification and monitoring at a massive scale. This enables ICUs to identify and anticipate patient acuity in advance which is critical to leveraging limited resources."
"COVID-19 is a major health concern that demands novel approaches, international cooperation and the sharing of strategies that work," said Gal Salomon, CLEW CEO. "At this time of great necessity, CLEW is pleased to be able to provide a meaningful contribution to the effort by making the very latest technologies available to the healthcare providers."
"Faced with a massive increase in ICU admissions, AI and machine learning tools can play a pivotal role in reducing disease severity and workload," said Prof. Ronni Gamzu, CEO of Tel Aviv Sourasky Medical Center. "Realtime risk stratification will enable timely interventions and improved clinical outcomes for critically ill patients."
CLEW is a real-time AI analytics platform designed to help providers make better informed clinical decisions by predicting life-threatening complications across various medical care settings. With CLEW, healthcare organizations can improve outcomes and safety, streamline patient care, and efficiently handle regulations and penalties, ultimately lowering the cost of care. The platform uses machine learning and data science technology to develop patient-specific physiological, predictive models to deliver predictive warnings during all phases of a patient's stay. Originally developed and proven in the ICU, these models optimize scarce clinical resources and guide health care providers in predicting patient deterioration, across all care settings. For more information visit clewmed.com
Media Contact: Cheryl Isen, +1 (425) 233-9032, [email protected]
An investigational device limited to investigational use only.